LncRNA FGD5-AS1 accelerates cell proliferation in pancreatic cancer by regulating miR-520a-3p/KIAA1522 axis

Lin, Jing; Liao, Shasha; Liu, Zewa; Li, E; Wu, Xiaohua; Zeng, Wanting

doi:10.1080/15384047.2021.1883184

Cited by 19 publications

(16 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 Another study consistently uncovered oncogenic roles of FGD5-AS1 in accelerating cell proliferation of pancreatic cancer through regulating the miR-520a-3p-KIAA1522 axis. 22 In colon cancer, FGD5-AS1 could induce cancer development, 8 suggesting that targeting FGD5-AS1 could be a potential therapeutic strategy against colon cancer.…”

Section: Discussionmentioning

confidence: 99%

Targeting EGFR sensitizes 5-Fu-resistant colon cancer cells through modification of the lncRNA-FGD5-AS1-miR-330-3p-Hexokinase 2 axis

Gao

Ren

Liu

et al. 2021

Molecular Therapy - Oncolytics

View full text Add to dashboard Cite

5-Fluorouracil (5-Fu) is a widely applied anti-cancer agent against colorectal cancer (CRC), yet a number of CRC patients have developed resistance to 5-Fu-based chemotherapy. The epidermal growth factor receptor (EGFR) is recognized as an oncogene that promotes diverse cancer progresses. In addition, long noncoding RNAs (lncRNAs) are essential regulators of cancers. Here we report that EGFR and lncRNA-FGD5-AS1 promoted 5-Fu resistance of CRC. By establishing the 5-Fu-resistant CRC cell line, we detected that EGFR, FGD5-AS1, and glucose metabolism were significantly elevated in 5-Fu-resistant CRC cells. A microRNA-microarray analysis revealed that miR-330-3p functions as a downstream effector of FGD5-AS1. FGD5-AS1 directly sponged miR-330-3p to form a competing endogenous RNA (ceRNA) network, leading to inhibition of miR-330-3p expression. Furthermore, bioinformatics analysis revealed that Hexokinase 2 (HK2) was a potential target of miR-330-3p, which was validated by luciferase assay. Rescue experiments demonstrated that FGD5-AS1 promotes glycolysis through modulating the miR-330-3p-HK2 axis, leading to 5-Fu resistance of CRC cancer cells. Finally, in vitro and in vivo xenograft experiments consistently demonstrated that inhibition of EGFR by the specific inhibitor erlotinib effectively enhanced the anti-tumor toxicity of 5-Fu by targeting the EGFR-FGD5-AS1-miR-330-3p-HK2 pathway. In summary, this study demonstrates new mechanisms of the EGFR-modulated 5-Fu resistance through modulating the noncoding RNA network, contributing to development of new approaches against chemoresistant CRC.

show abstract

Section: Discussionmentioning

confidence: 99%

Targeting EGFR sensitizes 5-Fu-resistant colon cancer cells through modification of the lncRNA-FGD5-AS1-miR-330-3p-Hexokinase 2 axis

Gao

Ren

Liu

et al. 2021

Molecular Therapy - Oncolytics

View full text Add to dashboard Cite

show abstract

“…lncRNAs are considered to be an important component of cancer, but they play different roles in different types of cancer. For instance, lncRNA FGD5-AS1 accelerates cell proliferation in pancreatic cancer by regulating the microRNA (miRNA or miR)-520a-3p/KIAA1522 axis ( 21 ), high expression levels of lncRNA PCAT1 are associated with drug resistance in colorectal cancer (CRC) ( 22 ) and lncRNA LNMICC promotes cervical cancer lymph node metastasis by reprogramming fatty acid metabolism ( 23 ). High or low expression of lncRNAs in tumours contributes to disease via multiple molecular mechanisms and they have a variety of unique functions and characteristics.…”

Section: Role Of Lncrnas In Cancermentioning

confidence: 99%

Roles of TGF‑β signalling pathway‑related lncRNAs in cancer (Review)

Liu

et al. 2023

Oncol Lett

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are a class of RNAs that are >200 nucleotides in length that do not have the ability to be translated into protein but are associated with numerous diseases, including cancer. The involvement of lncRNAs in the signalling of certain signalling pathways can promote tumour progression; these pathways include the transforming growth factor (TGF)-β signalling pathway, which is related to tumour development. The expression of lncRNAs in various tumour tissues is specific, and their interaction with the TGF-β signalling pathway indicates that they may serve as new tumour markers and therapeutic targets. The present review summarized the role of TGF-β pathway-associated lncRNAs in regulating tumorigenesis in different types of cancer and their effects on the TGF-β signalling pathway.

show abstract

“…In pancreatic adenocarcinoma (PAAD), FGD5-AS1 also functions as an oncogene and thus can expedite the proliferation, metastasis, and invasion of PAAD cells. Silencing FGD5-AS1 can reverse the inhibitory effect of miR-520a-3p on KIAA1522, thereby attenuating the progression of PAAD [ 73 ]. Consequently, FGD5-AS1 is a promising prognostic and therapeutic target for LSCC, PC, and melanoma.…”

Section: Motor Systemmentioning

confidence: 99%

“…LncRNA-FGD5-AS1 is a newly discovered lncRNA that has attracted considerable from researchers. Abnormally high expression of FGD5-AS1 has been reported in lung cancer [ 21 , 39–42 ], liver cancer [ 34 , 35 ], cervical cancer [ 53 ], osteosarcoma [ 69 , 70 ], glioma cancer [ 61–64 ], colorectal cancer [ 22 , 37 ], oral cancer [ 28 , 29 ], ovarian cancer [ 55 , 56 ], breast cancer [ 23 , 45 ], gastric cancer [ 30 , 31 ], pancreatic cancer [ 73 ], melanoma [ 72 ], and laryngeal squamous cell carcinoma [ 71 ] and is associated with poor prognosis in these cancers. However, several studies have also reported that FGD5-AS1 inhibits cancer.…”

Section: Future Perspectivesmentioning

confidence: 99%

The role of long non-coding RNA FGD5-AS1 in cancer

Xiang

Chen

et al. 2022

Bioengineered

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) refers to a class of RNAs that have at least 200 nucleotides and do not encode proteins, and the relationship between lncRNA and cancer has recently attracted considerable research attention. The lncRNA FGD5-AS1 is a newly discovered lncRNA with a length of 3772 nucleotides. Studies have found that FGD5-AS1 is abnormally highly expressed in many cancer tissues and was closely related to the lymph node metastasis, tumor invasion, survival time, and recurrence rate of various cancers. Mechanistic analyses show that FGD5-AS1 can stabilize mRNA expression by sponging miRNA, which not only induces cancer cell proliferation, metastasis, invasion, and chemoresistance in vitro, but also promotes tumor growth and metastasis in vivo. In addition, FGD5-AS1 can serve as a diagnostic or prognostic marker for a variety of cancers. This review demonstrates the clinical significance of FGD5-AS1 in human cancer and its role in tumorigenesis and tumor progression.

show abstract

LncRNA FGD5-AS1 accelerates cell proliferation in pancreatic cancer by regulating miR-520a-3p/KIAA1522 axis

Cited by 19 publications

References 29 publications

Targeting EGFR sensitizes 5-Fu-resistant colon cancer cells through modification of the lncRNA-FGD5-AS1-miR-330-3p-Hexokinase 2 axis

Targeting EGFR sensitizes 5-Fu-resistant colon cancer cells through modification of the lncRNA-FGD5-AS1-miR-330-3p-Hexokinase 2 axis

Roles of TGF‑β signalling pathway‑related lncRNAs in cancer (Review)

The role of long non-coding RNA FGD5-AS1 in cancer

Contact Info

Product

Resources

About